U.S. markets closed

Pressure BioSciences, Inc. (PBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.7700+0.0800 (+4.73%)
At close: 3:32PM EDT
Full screen
Loading interactive chart...
  • Pressure BioSciences Achieves Critical Milestone in Revolutionary Nanoemulsification Technology Development; Enters Production Era for Commercial System Development
    PR Newswire

    Pressure BioSciences Achieves Critical Milestone in Revolutionary Nanoemulsification Technology Development; Enters Production Era for Commercial System Development

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("UST™")-based nanoemulsification system. Following achievement of this milestone, the Company has begun to build the initial "Alpha" unit of the commercial model. Once built, tested, and approved, the Company will immediately proceed to build an additional 15 ready-for-sale systems, thus enabling PBI to meet its goal of shipping the BaroShear K45 UST System in early (Q1/Q2) 2021.

  • Pressure BioSciences Awarded Pivotal U.S. Patent for Novel, High Pressure Enhanced Consumable Device
    PR Newswire

    Pressure BioSciences Awarded Pivotal U.S. Patent for Novel, High Pressure Enhanced Consumable Device

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide Life Sciences and other industries, today announced the award of a key U.S. patent entitled "Sample Preparation Devices and Methods". This new patent (US 10,710,082) brings the Company's Intellectual Property ("IP") estate up to a total of 25 issued patents.

  • Pressure BioSciences First Quarter 2020 Financial and Business Update to Include Jim Morrison, In-Coming CEO for Merged Companies of Availa Bio
    PR Newswire

    Pressure BioSciences First Quarter 2020 Financial and Business Update to Include Jim Morrison, In-Coming CEO for Merged Companies of Availa Bio

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2020 financial results and to provide a business update, including discussions on progress made in the development of the Company's proprietary Ultra Shear Technology™ ("UST™) Platform and in the pending merger of PBI, Cannaworx, and SkinScience Labs.